ACUTE MYELOID LEUKEMIA (AML)

This early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …

This large Phase 3 trial is testing whether adding the experimental drug ziftomenib to standard chemotherapy helps people with untreated acute myeloid leukemia (AML) who have specific genetic mutations. About 1,300 participants will be randomly assigned to receive either ziftomen…

This early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cel…

This early-stage trial tests whether combining the drugs gilteritinib with ivosidenib or enasidenib is safe for people with acute myeloid leukemia (AML) that has returned or not responded to treatment. Participants must have specific gene mutations (FLT3 and IDH1 or FLT3 and IDH2…

This phase 2 study tests whether the drug ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 75 adults with a specific IDH1 gene mutation will receive either ivosidenib or a placebo daily. The main goal is to see if the d…

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…

This study tests an experimental drug called ziftomenib in 6 Japanese adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drug is taken as a pill once daily. The goal is to see if it can help control the disease and how…

This early-stage study tests an experimental drug called APL-4098, alone or with standard treatments, in adults with acute myeloid leukemia (AML) or related blood disorders. The goal is to find a safe dose and see if it shrinks cancer. About 100 people will take part.

This early-phase trial is testing a new treatment called CART123 for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. CART123 cells are specially engineered immune cells designed to find and kill leukemia cells. …

This study tests a combination of five drugs (VABu) given before a stem cell transplant in people aged 60 and older with acute myeloid leukemia (AML). The goal is to see if this approach can help control the disease and improve survival. About 20 participants will receive the tre…

This study tests a combination of two drugs—ivosidenib (a daily pill) and azacitidine (an injection or infusion)—in adults newly diagnosed with a type of acute myeloid leukemia (AML) that has an IDH1 gene mutation. The participants are not healthy enough for standard intensive ch…

This phase 2 trial tests whether adding metal detoxification drugs (DMSA and Ca-EDTA) to standard therapy can improve outcomes for adults with intermediate- to high-risk acute myeloid leukemia (AML). Researchers believe lowering metal levels in blood and bone marrow may help cont…

This study tests a precise type of radiation called proton total marrow irradiation (TMI) given before a stem cell transplant for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see if adding TMI to standard chemotherapy is saf…

This Phase 3 trial tests whether the drug gilteritinib is better than sorafenib at keeping leukemia from coming back in patients with a specific gene mutation (FLT3-ITD) after a stem cell transplant. About 594 adults and teens will take one of the two pills daily for up to 2 year…

This study is testing whether a combination of three drugs—venetoclax, a hypomethylating agent (azacitidine or decitabine), and low-dose cytarabine—can effectively treat adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CEBPA-mutated AML) who are n…

This phase 2 trial tests whether two drugs, azacitidine and venetoclax, can eliminate or reduce measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who have completed standard chemotherapy and are scheduled for a donor stem cell transplant. The goal is t…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests a new drug called STX-0712 in people with advanced types of blood cancer (CMML or AML) who have run out of standard treatments. The main goal is to find a safe dose and see how the body handles the drug. About 105 participants will take part in this early-phase t…

This program offers early access to venetoclax, a targeted cancer pill, for people with certain blood cancers like leukemia or lymphoma who have no other good treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved in all…

This early-phase trial tests niclosamide, a drug previously used for tapeworm infections, combined with standard chemotherapy in 16 children whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find a safe dose and check for side effe…

This early-stage trial is testing a new type of immune cell therapy called supCD7 CART cells in 12 adults with relapsed or refractory CD7-positive blood cancers (T-cell leukemia/lymphoma or acute myeloid leukemia). The cells are designed to target and kill cancer cells that carry…

This phase 2 trial tests whether adding two drugs, ruxolitinib and abatacept, to standard transplant care can prevent graft-versus-host disease (GVHD) in 60 patients with high-risk myeloid cancers like AML and MDS. Participants receive a stem cell transplant from a partially matc…

This early-stage trial is testing a new treatment called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. A-CAR028 is a type of immune cell therapy (CAR-T) that is designed to recognize and attack leukemia cells by tar…

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…

This early-phase study is testing a new type of immune cell therapy called universal CD7 CAR-T (uCD7 CART) in people with relapsed or refractory acute myeloid leukemia (AML) or T-cell leukemia/lymphoma. The cells are designed to target and kill cancer cells that carry the CD7 pro…

This study looks at whether measuring the amount of venetoclax in the blood can help doctors give the right dose to people with newly diagnosed acute myeloid leukemia (AML). Currently, everyone gets the same dose, but drug levels vary a lot between patients. The goal is to find a…

This registry study is collecting medical information and biological samples from 15,000 adults with acute myeloid leukemia (AML) across 60 German hospitals. Researchers aim to track patient outcomes, treatment patterns, and disease characteristics to better understand AML. No ne…

This observational study looks at whether leukemia stem cells can predict if acute myeloid leukemia (AML) with MLL rearrangement will come back. Researchers will measure these stem cells in bone marrow samples taken during regular check-ups. The goal is to improve relapse predict…

This study is testing a new, highly sensitive blood test (digital PCR) to find tiny amounts of leukemia cells that remain after a stem cell transplant in people with acute myeloid leukemia (AML). The goal is to see if this test can predict a relapse earlier than current methods. …

This study is a registry that collects information from up to 50,000 adults with acute myeloid leukemia (AML) or related blood cancers. Researchers will track patients' genetics, treatment responses, and long-term outcomes over up to 10 years. The goal is to better understand the…

This study follows 5,000 adults with acute myeloid leukemia (AML) in French hospitals to see how they are actually treated and how they fare over time. Researchers will collect data on treatments, survival, and disease progression for up to 10 years. The goal is to understand rea…

This study is a registry that tracks patients with blood diseases who receive stem cell transplants at a hospital on the Qinghai-Tibet Plateau. Researchers will collect information on recovery, complications, and costs over time. The goal is to understand how high altitude affect…